HERVolution Therapeutics develops immunotherapies that target human endogenous retroviruses (HERVs) from the ‘dark genome’ to treat cancer, metabolic disease and other aging-related conditions. The company uses proprietary engineering to break immune self-tolerance and induce potent, durable anti-HERV T and B cell responses. Re-designed HERV antigens can be delivered via adenoviral vectors, virus-like particles, and mRNA, enabling off-the-shelf applications and varied dosing regimens. Its lead candidate, IPT-001, is a dual adenoviral-vector immune therapy supported by robust preclinical data and developed in collaboration with the Serum Institute of India; HERVolution plans to enter the clinic in 2025. The company is also developing IPT-002, an mRNA vector intended for prime-boost strategies to maintain and amplify anti-HERV responses. HERVolution announced an $11.7M Series A to fund cGMP manufacturing with SII, initiate Phase 1 studies, investigate indication expansion, and expand clinical infrastructure. The company is based in Copenhagen, Denmark and the U.S., and was formerly InProTher Aps.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2024